Alcentra Global Policies
Alcentra Order Execution Policy
Following the global regulatory directive, Alcentra has embarked throughout 2021 on a significant change programme to successfully transition away from the usage of unsecured Interbank Offered Rates (IBORs), and towards the integration of Risk Free Rates (RFRs).
As at 31st December 2021, GBP, JPY, EUR and CHF LIBOR , across all tenors (overnight, 1week, 3mth, 6mth, 12mth and USD (1 week, 2mth) will either permanently cease or will no longer be considered to be representative rates, and as such will be replaced, in line with industry recommendations, by their secured overnight equivalent (SONIA, TONAR, ESTR, SARON and SOFR).
Alcentra has reviewed the impacts of such change across all business functions and has made a number of positive upgrades to our technology and operational architecture to support the smooth integration of these new rates. Additionally, Alcentra have successfully remediated all applicable legal documentation to incorporate adequate fallback language in readiness for the end of year deadline. This has seen a change to a small number of fund performance benchmarks which previously tracked LIBOR, and to a number of internal lending agreements.
As predominantly a ‘rate-taker’, rather than a ‘rate-setter’ in the market, Alcentra has also maintained close engagement with third parties throughout the transition period to oversee the amendment by Issuers of asset holdings with underlying LIBOR exposure to RFRs.
Alcentra’s Change Management Team will now turn their attention to prepare the business for the second wave of IBOR transformation; the scheduled permanent cessation or loss of representativeness of USD LIBOR (all remaining tenors) in June 2023, starting in the first instance with no new USD LIBOR deals being engaged by the business from 2022.
Following recent reform, EURIBOR continues to be a representative rate and is therefore not in scope for transition at this stage.
Alcentra Limited is incorporated in England.
Alcentra Limited is authorised and regulated by the Financial Conduct Authority.
Alcentra Limited is registered as an investment adviser with the Securities and Exchange Commission with respect to its US clients.
160 Queen Victoria Street
London EC4V 4LA
Registration number 2958399
Incorporated in England and Wales
Pillar 3 Disclosure as at 31st December 2021
Pillar 3 Disclosure as at 31st December 2020
Pillar 3 Disclosure as at 31st December 2019
Pillar 3 Disclosure as at 31st December 2018
Pillar 3 Disclosure as at 31st December 2017
Pillar 3 Disclosure as at 31st December 2016
Pillar 3 Disclosure as at 31st December 2015
Alcentra MiFID II – RTS 28 Disclosures FY 2020
Alcentra MiFID II – RTS 28 Disclosures FY 2019
Alcentra MiFID II – RTS 28 Disclosures FY 2018
Alcentra MiFID II – RTS 28 Disclosures FY 2017
Calls to Alcentra Limited may be recorded in line with applicable laws and regulations and for training and monitoring purposes.
Alcentra NY, LLC
Alcentra NY, LLC is incorporated in Delaware, USA
Alcentra NY, LLC is registered as an investment adviser with the Securities and Exchange Commission with respect to its US clients.
Alcentra New York
9 West 57th Street
New York, NY 10019
Alcentra High Yield
399 Boylston Street
Boston, MA 02116
A division of Alcentra NY, LLC
Complaints may be submitted via email to the Global Head of Investor Relations at [email protected] or in writing to:
Alcentra Group, 160 Queen Victoria Street, London, ECV4 4LA
Alcentra will acknowledge complaints in writing within three business days of receipt and will investigate the complaint. Alcentra will be transparent in our investigation, will not charge any fees for the investigation and will work to reach an agreeable solution as quickly as possible with the aim to have the complaint resolved within three business days. Business days are Monday to Friday excluding Bank Holidays. If the complaint cannot be resolved within 30 days, Alcentra will keep the complainant informed of the progress of the complaint every 14 days.
Following an investigation, Alcentra will notify you by email or in writing of the outcome.
If you are dissatisfied with the response to your compliant and wish to escalate the matter, please contact Alcentra’s Global Head of Compliance: [email protected]